78-70-6
Chemical Structure
Linalool,98% (stabilized with MEHQ)
- CAS No.: 78-70-6
- Formula:C10H18O
- Molecular Weight:154.25
IUPAC Name: 3,7-dimethylocta-1,6-dien-3-ol
InChIKey: CDOSHBSSFJOMGT-UHFFFAOYSA-N
SMILES: C=CC(O)(C)CC/C=C(C)/C
Biological Activity: Linalool is a natural monoterpene which is a competitive NMDA receptor antagonist. Linalool is orally active and crosses the blood-brain barrier. Linalool has anticancer, antibacterial, anti-inflammatory, neuroprotective, anxiolytic, antidepressant, anti-stress, cardioprotective, hepatoprotective, nephroprotective and pulmonary protective activities[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Linalool,98% (stabilized with MEHQ) | 99.04% | Linalool is a natural monoterpene which is a competitive NMDA receptor antagonist. Linalool is orally active and crosses the blood-brain barrier. Linalool has anticancer, antibacterial, anti-inflammatory, neuroprotective, anxiolytic, antidepressant, anti-stress, cardioprotective, hepatoprotective, nephroprotective and pulmonary protective activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Linalool (Standard) | 97.16% | Linalool (Standard) is the analytical standard of Linalool. This product is intended for research and analytical applications. Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity.Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Linalool-d3 | 95.17% | Linalool-d3 is the deuterium labeled Linalool. Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity.Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Linalool-13C3 | Linalool-13C3 is 13C labeled Linalool (HY-N0368). Linalool is a natural monoterpene which is a competitive NMDA receptor antagonist. Linalool is orally active and crosses the blood-brain barrier. Linalool has anticancer, antibacterial, anti-inflammatory, neuroprotective, anxiolytic, antidepressant, anti-stress, cardioprotective, hepatoprotective, nephroprotective and pulmonary protective activities. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Linalool-d5 | ≥99.0% | Linalool-d5 is the deuterium labeled Linalool (HY-N0368). Linalool is a natural monoterpene which is a competitive NMDA receptor antagonist. Linalool is orally active and crosses the blood-brain barrier. Linalool has anticancer, antibacterial, anti-inflammatory, neuroprotective, anxiolytic, antidepressant, anti-stress, cardioprotective, hepatoprotective, nephroprotective and pulmonary protective activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Oner Z1, et al. The protective and therapeutic effects of linalool against doxorubicin-induced cardiotoxicity in Wistar albino rats. Hum Exp Toxicol. 2019 Apr 12:960327119842634. [Content Brief]
- [2]. Jun HJ, et al. Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110. [Content Brief]
- [3]. Jana S, et al. Antitumorigenic potential of linalool is accompanied by modulation of oxidative stress: an in vivo study in sarcoma-180 solid tumor model. Nutr Cancer. 2014;66(5):835-48. [Content Brief]
- [4]. Rodenak-Kladniew B, et al. Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells. Heliyon. 2020 Dec 15;6(12):e05639. [Content Brief]
- [5]. An Q, et al. Recent updates on bioactive properties of linalool. Food Funct. 2021 Nov 1;12(21):10370-10389. [Content Brief]